EXHIBIT 10.33

2
EXHIBIT 10.33

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
NOTICE OF GRANT AWARD

TYPE OF AWARD: RESEARCH
AUTHORIZED BY: 42 USC 241 42 CFR 52

DATE ISSUED: 04/26/91

GRANT NUMBER: GNM 1 R01 HG00122-O1A1

TOTAL PROJECT PERIOD: From 05/01/91 Through /4/30/94

AWARDED BY: NATIONAL CENTER FOR HUMAN GENOME RESEARCH

Title of Project or Area of Training: A PHYSICAL & REFINED GENETIC MAP OF HUMAN
CHROMOSOME 10

Grantee Organization
Collaborative Research, Inc.
Two Oak Park
Bedford, MA 01730

Principal Investigator/Program Director/ Awardee
MAO, JEN-I PHD
Collaborative Research, Inc.
Human Genetics & Molecular Bio
Two Oak Park
Bedford, MA 01730

APPROVED BUDGET
FOR BUDGET PERIOD 05/01/91 Through 04/30/92

Salaries and Wages................................ $136,650
Fringe Benefits ................................... 40,995
Total Personnel Costs................................. $177,645
Consultant Costs...........................................
Equipment.................................................. 41,000
Supplies................................................... 86,000
Travel-Domestic............................................ 1,500
-Foreign.......................................... 4,000
Patient Care--Inpatient....................................
--Outpatient.....................................
Alterations and Renovations................................
Consortium/Contractual Costs...............................
Other......................................................
.........................................
Trainee Stipends...........................................
Trainee Tuition and Fees...................................
Trainee Travel ............................................

TOTAL DIRECT COSTS ->.................................. $310,145

When PHS Prior Approval is required for rebudgeting, submit requests to Grants
Management Official below.

AWARD COMPUTATION
DIRECT COSTS................................................ $310,145
INDIRECT COSTS.............................................. $242,231
--------

TOTAL .................................................... $552,376

Less Unobligated Balance [Prior Period(s)].................. $ 0

AMOUNT OF THIS AWARD ->..................................... $552,376

Base dollars x Rate Percentage = Indirect Costs $
269,145 90.00 242,231

SUPPORT RECOMMENDED FOR REMAINDER OF PROJECT PERIOD**
Budget Total Direct Costs Stipends
Period (Includes Stipends)

02 294,143
03 305,787
04 NONE

**Subject to availiability of funds and satisfactory progress.

- --------------------------------------------------------------------------------
REMARKS
This Grant is included under Expanded Authorities (PHS Circular 89.02) - See
NIH Guide for Grants and Contracts, Vol. 18, No. 36, 10/13/89.

Grants Management Contact: Cheryl L. Holleran (301) 402-0733
Program Administrator: Dr. Bettie J. Graham (301) 496-7531

See page 2 for Additional Remarks.
- --------------------------------------------------------------------------------

Terms of Acceptance: By acceptance of funds awarded under this grant, the
grantee acknowledges that it will comply with terms and conditions in the
following: (1) Legislation cited above; (2) Regulations cited above; (3) Special
provisions noted above under remarks or attached to this notice; (4) CFR Part 74
or 92, as applicable; (5) PHS Grants Administration Manual; (6) PHS Grants
Policy Statement. The above order of precedence shall prevail.

FY- Common Accounting Number: 1-8427201

CRS/ Entity Identifaction No.: 1042297484A1

PHS List No./Object Class Code: /41.4A

Document Number: (08)R1HG00122A

-2-

PROGRAM OFFICIAL
/S/ Bettie J. Graham
BETTIE J. GRAHAM, PH.D.
CHIEF, RESEARCH GRANTS BRANCH
NATIONAL CENTER FOR HUMAN
GENOME RESEARCH

PHS GRANTS MANAGEMENT OFFICIAL
/s/ Alice H. Thomas
ALICE H. THOMAS
GRANTS MANAGEMENT OFFICER
NATIONAL CENTER FOR HUMAN
GENOME RESEARCH

-3-

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
NOTICE OF GRANT AWARD

TYPE OF AWARD: REASEARCH
AUTHORIZED BY: 42 USC 241 42 CFR 52

DATE ISSUED: 05/29/92

GRANT NUMBER: GNM 5 R01 HG00122-02

TOTAL PROJECT PERIOD: From 05/01/91 Through 04/30/94

AWARDED BY: NATIONAL CENTER FOR HUMAN GENOME RESEARCH

Title of Project or Area of Training: PHYSICAL & REFINED GENETIC MAP OF
HUMAN CHROMOSOME 10

Grantee Organization
Collaborative Research, Inc.
1365 Main Street
Waltham, MA 02154

Principal Investigator/Program Director/ Awardee
MAO, JEN-I PHD
Collaborative Research, Inc.
Human Genetics & Molecular Bio
1365 Main Street
Waltham, MA 02154

APPROVED BUDGET
FOR BUDGET PERIOD 05/01/92 Through 04/30/93

Salaries and Wages...................................................$150,756
Fringe Benefits .......................................................45,227
Total Personnel Costs................................................... $195,983
Consultant Costs.............................................................
Equipment ........................................................... 3,000
Supplies ........................................................... 89,440
Travel-Domestic.............................................................. 1,560
-Foreign............................................................
Patient Care--Inpatient......................................................
--Outpatient.......................................................
Alterations and Renovations..................................................
Consortium/Contractual Costs................................................. 4,160
Other ...........................................................
...........................................................
Trainee Stipends.............................................................
Trainee Tuition and Fees.....................................................
Trainee Travel...............................................................

-4-

TOTAL DIRECT COSTS ->.................................................. $294,143

When PHS Prior Approval is required for rebudgeting, submit requests to Grants
Management Offical below.

AWARD COMPUTATION
DIRECT COSTS................................................................ $294,143
INDIRECT COSTS.............................................................. $262,029
--------
TOTAL ...................................................................... $556,172

Less Unobligated Balance [Prior Period(s)].................................. $ 0

AMOUNT OF THIS AWARD ->..................................................... $556,172

Base dollars x Rate Percentage = Indirect Costs $
269,143 90.00 262,029

SUPPORT RECOMMENDED FOR REMAINDER OF PROJECT PERIOD**
Budget Total Direct Costs Stipends
Period (Includes Stipends)

03 305,787
04 NONE

**Subject to availiability of funds and satisfactory progress.

- --------------------------------------------------------------------------------
REMARKS
This Grant is included under Expanded Authorities (PHS Grants Policy Statement
Revised 10/01/90)

Grants Management Contact: Linda Hall (301) 402-0733
Program Administrator: Dr. Bettie Graham (301) 496-7531

See attached for terms of acceptance and any additional terms and conditions.
- --------------------------------------------------------------------------------

FY- Common Accounting Number: 2-8427201

CRS/ Entity Identification No.: 1042297484A1

PHS List No./Object Class Code: /41.4E

Document Number: (08)R1HG00122A

PROGRAM OFFICIAL
/S/ Bettie J. Graham
BETTIE J. GRAHAM, PH.D.
CHIEF, RESEARCH GRANTS BRANCH

-5-

NATIONAL CENTER FOR HUMAN
GENOME RESEARCH

PHS GRANTS MANAGEMENT OFFICIAL
/S/ Alice H. Thomas
ALICE H. THOMAS
GRANTS MANAGEMENT OFFICER
NATIONAL CENTER FOR HUMAN
GENOME RESEARCH

PHS 1533 920521 1337 Copies distributed to Principal Investigator, Program
Director or Awardee, and Business Office DKP

-6-

NOTICE OF GRANT AWARD

Page 2
5 R01 HG00122-03
MAO, JEN-I Ph.D.

TERMS AND CONDITIONS

Terms of acceptance: This grant is subject to the terms and conditions
incorporated either directly or by reference in the following: (1) The grant
program legislation cited on the first page; (2) The grant program regulations
cited on the first page; (3) This award notice including terms and conditions,
if any, noted below or attached to this notice; (4) PHS Grants Policy Statement
including addenda in effect as of the beginning date of the budget period; and
(5) 45 CFR Part 74 or 92 as applicable. In the event there are conflicting or
otherwise inconsistent policies applicable to the grant, the above order of
precedence shall prevail. Acceptance of the grant terms and conditions is
acknowledged by the grantee when funds are drawn or otherwise obtained from the
grant payment system.

1. Unobligated funds from the 01 year may be carried over to the 02 year,
however, no additional funds over those originally recommended for the 02 year
are approved. Any expenses covered by carry-over funds are considered one-time
costs only and will not affect the out years.

2. General Program Income is to be treated under the Additional Costs
Alternative, per the PHS GRANTS POLICY STATEMENT.

-7-

NOTICE OF GRANT AWARD
(Additional Remarks)

Page 3

If you need assistance from the ICD during the course of this grant, please
contact the grants management and program staff whose telephone numbers are
shown on the Notice of Grant Award. These individuals work closely with one
another through all phases of each project to facilitate the award and the
administration of the grant. Their functions are defined as follows:

GRANTS MANAGEMENT CONTACT: The Grants Management Specialist, whose name and
telephone number are indicated in the "Remarks" section of the Notice of Grant
Award, is responsible for all business management matters associated with the
review, negotiation, award, and administration of grants. Grants Management
Specialists serve as the focal point for receiving and responding to all
questions and correspondence related to business management and policy matters,
such as correspondence giving or denying any prior approval required by Public
Health Service policy or special Terms of Award, transfer of the grant to
another institution, a change in the period of support, or any actions which
commit, or may result in committing the ICD to a change in the amount of
funding.

PROGRAM CONTACT: The Health Science Administrator, or program official, whose
name and telephone number also are indicated in the "Remarks" section of the
Notice of Grants Award, is responsible for all scientific and technical matters
dealing with the administration of grants. The Health Science Administrator
reviews and monitors scientific progress of the project and provides advice and
assistance relative to all technical problems to ensure that the scientific
objectives of the research program can be pursued effectively and successfully.
All questions or correspondence dealing with research progress, changes in
research direction, unique scientific opportunities, or any other scientific
needs should be addressed to the Health Science Administrator.

PRIOR APPROVAL: Requests which require the approval of the ICD must be submitted
in writing to the Grants Management Officer. All requests should reference the
complete grant number, e.g. 1 R01 HG-12345-01, and must be signed by the
authorized official of the business office of the grantee institution and by the
principal investigator.

-8-

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
National Institutes of Health
National Center for Human Genome Research

NOTICE OF GRANT AWARD
AUTHORIZATION (Legislation/Regulation)

42 USC 241 42 CFR 52
RESEARCH

1. DATE ISSUED (Mo./Day/Yr.): 04/07/93

2. CFDA NO.: 93.172

3. SUPERSEDES AWARD NOTICE dated __________________ except that any
additions or restrictions previously imposed remain in effect unless
specifically rescinded.

4. GRANT NO.: 5 R01 HG00122-03

Formerly:

5. ADMINISTRATIVE CODES: B2G

6. PROJECT PERIOD Mo./Day/Yr.: From 05/01/91 Through 04/30/94

7. BUDGET PERIOD Mo./Day/Yr.: From 05/01/93 Through 04/30/94

8. TITLE OF PROJECT (OR PROGRAM) (Limit to 56 spaces): Physical & Refined
Genetic Map of Human Chromosome 10 GNM

9. GRANTEE NAME AND ADDRESS:

Collaborative Research, Inc.
1365 Main Street
Waltham, MA 02154

10. DIRECTOR OF PROJECT (PROGRAM DIRECTOR/PRINCIPAL INVESTIGATOR) (LAST NAME
FIRST AND ADDRESS):

MAO, JEN-I PHD
Collaborative Research, Inc.
Human Genetics & Molecular BIO
1365 Main Street
Waltham, MA 02154

-9-

11. APPROVED BUDGET (Excludes PHS Direct Assistance)

I PHS Grant Funds Only
/ I /

II Total project costs including grant funds and all
other financial participation

(SELECT ONE AND PLACE NUMERAL IN BOX.)

a. Salaries and Wages.................................$156,787
b. Fringe Benefits.....................................$47,035
c. Total Personnel Costs................................. $203,822
d. Consultant Costs........................................... 0
e. Equipment.................................................. 3,000
f. Supplies................................................... 93,017
g. Travel..................................................... 1,560
h. Patient Care--Inpatient.................................... 0
i. --Outpatient................................... 0
j. Alterations and Renovations................................ 0
k. Other...................................................... 4,388
l. Consortium/Contractual Costs............................... 0
m. Trainee Related Expenses...................................
n. Trainee Stipends........................................... 0
o. Trainee Tuition and Fees................................... 0
p. Trainee Travel............................................. 0
q. TOTAL DIRECT COSTS ->................................. $205,787
r. INDIRECT COSTS (Rate* % of S&W/TADC)................. $272,568
s. TOTAL APPROVED BUDGET...................................... $578,295
t. SBIR Fee................................................... $ 0
u. Federal Share.............................................. $578,295
v. Non-Federal Share..........................................

12. AWARD COMPUTATION FOR FINANCIAL ASSISTANCE

a. Amount of PHS Financial Assistance (from Item 11.u.).......... $578,295
b. Less Unobligated Balance From Prior Budge Periods............. $ 0
c. Less Cumulative Prior Award(s) This Budget Period............. $ 0
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION.................... $578,295

13. RECOMMENDED FUTURE SUPPORT (SUBJECT TO THE AVAILABILITY OF FUNDS AND
SATISFACTORY PROGRESS OF THE PROJECT):

- -------------------------------------------------------------------------------------------------------------------
YEAR TOTAL DIRECT COSTS/STIPENDS YEAR TOTAL DIRECT COSTS/STIPENDS
- -------------------------------------------------------------------------------------------------------------------

a. d.
- -------------------------------------------------------------------------------------------------------------------
b. e.
- -------------------------------------------------------------------------------------------------------------------
c. f.
- -------------------------------------------------------------------------------------------------------------------

-10-

14. APPROVED DIRECT ASSISTANCE BUDGET (IN LIEU OF CASH):

a. Amount of PHS Direct Assistance................................. $
b. Less Unobligated Balance From Prior Budget Periods.............. $
c. Less Cumulative Prior Award(s) This Budget Period............... $
d. AMOUNT OF DIRECT ASSISTANCE THIS ACTION......................... $

15. PROGRAM INCOME SUBJECT TO 45 CFR PART 74, SUBPART F, OR 45 CFR 92.25,
SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:
(Select One and Place LETTER in box.)

/ A /
a. DEDUCTION
b. ADDITIONAL COSTS
c. MATCHING
d. OTHER RESEARCH (Add/Deduct Option)
e. OTHER (See REMARKS)

16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY,
THE PHS ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND
CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE
FOLLOWING:

a. The grant program legislation cited above.
b. The grant program regulation cited above.
c. This award notice including terms and conditions, if any,
noted below under REMARKS.
d. PHS Grants Policy Statement including addenda in effect
as of the beginning date of the budget period.
e. 45 CFR part 74 or 45 CFR Part 92 as applicable.

IN THE EVENT THERE ARE CONFLICTING OR OTHERWISE INCONSISTENT POLICIES
APPLICABLE TO THE GRANT, THE ABOVE ORDER OF PRECEDENCE SHALL PREVAIL.
ACCEPTANCE OF THE GRANT TERMS AND CONDITIONS IS ACKNOWLEDGED BY THE
GRANTEE WHEN FUNDS ARE DRAWN OR OTHERWISE OBTAINED FROM THE GRANT
PAYMENT SYSTEM.

- --------------------------------------------------------------------------------
REMARKS: (Other Terms and Conditions Attached -- / / Yes / / No)

Grant Specialist: Linda Hall (301) 402-0733
Program Official: Dr. Bettie J. Graham (301) 496-7531

* Base X Rate ($302,787 X 90.00)

This Grant is included under expanded authorities.
- --------------------------------------------------------------------------------

PHS GRANTS MANAGEMENT OFFICER: (Signature)
/s/ Jean M. Cahill
(Name-Typed/Print) (Title)
Jean M. Cahill Grants Management Officer

17. OBJ. CLASS: 41.4E

18. CRS - EIN: 1042297484A1

-11-

19. LIST NO.:

- ---------------------------------------------------------------------------------------------------------------------------
FY-CAN DOCUMENT NO. ADMINISTRATIVE AMT. ACTION FIN. AMT. ACTION DIR.
CODE ASST. ASST.
- ---------------------------------------------------------------------------------------------------------------------------

20.a. 93 8427201 b. R1HG00122A c. d. e.

21.a. b. c. d. e.

22.a. b. c. d. e.
- ---------------------------------------------------------------------------------------------------------------------------

-12-

NOTICE OF GRANT AWARD

Page 2
5 R01 HG00122-03
MAO, JEN-I Ph.D.

1. The Appropriations Act prohibits reimbursement of direct salary for
individuals at a rate greater than $125,000 a year as determined in the original
award. The language contained in the Appropriations Act follows:

"None of the funds appropriated in this title for the National Institutes
of Health and the Alcohol, Drug Abuse, and Mental Health Administration
shall be used to pay the salary of an individual, through a grant or other
extramural mechanism, at a rate in excess of $125,000 per year."

2. Allowable activities conducted by for-profit organizations will be determined
by applying the cost principles of contracts with Commercial Organizations set
forth in 48 CFR Subpart 31.2. Independent research and development costs are
unallowable.

3. All prior approvals, where required, remain with the awarding unit.

4. This grant is in the final budget period. Unless an application for
competitive renewal is funded, grant closeout documents must be submitted within
90 days of the end of the current budget period. Documents required are a
Financial Status Report (FSR), Final Invention Statement and Final Progress
Report. The Final Progress Report may be typed on plain white paper and should
include, at a minimum, a summarization of progress toward the achievement of the
originally stated aims, a list of results (positive or negative) considered
significant, and a list of publications resulting from the project as well as a
plan for future publications. An original and one copy are required. Please send
the Final Progress Report and Invention Statement to the following address:

National Center for Human Genome Research
Grants & Contracts Management Section
9000 Rockville Pike
Building 38A, Room 613
Bethesda, MD 20892

The Final FSR should be sent to:

National Institutes of Health
Division of Financial Management
9000 Rockville Pike
Building 31, Room B1B-11
Bethesda, MD 20892

-13-

NOTICE OF GRANT AWARD

Page 3
5 R01 HG00122-03
MAO, JEN-I Ph.D.

5. Title to equipment acquired under this grant shall vest upon acquisition in
the Federal Government and be accounted for as outlined in the publication
entitled, "Control of Property in the Possession of Contractors." The property
administrator for the grant is:

Research Contracts Property Administrator
Personal Property Branch
National Institutes of Health
Building 13, Room 2E65D
Bethesda, MD 20892
Phone (301) 496-6467

-14-

NOTICE OF GRANT AWARD
(Additional Remarks)

Page 4

-15-

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
National Instititutes of Health
National Center for Human Genome Research

NOTICE OF GRANT AWARD
AUTHORIZATION (Legislation/Regulation)

42 USC 241 42 CFR 52
RESEARCH

1. DATE ISSUED (Mo./Day/Yr.): 04/22/94

2. CFDA NO.: 93.172

3. SUPERSEDES AWARD NOTICE dated __________________ except that any
additions or restrictions previously imposed remain in effect unless
specifically rescinded.

4. GRANT NO.: 2 R01 HG00122-04

Formerly:

5. ADMINISTRATIVE CODES: M2BG

6. PROJECT PERIOD Mo./Day/Yr.: From 05/01/91 Through 04/30/97

7. BUDGET PERIOD Mo./Day/Yr.: From 05/01/94 Through 04/30/95

8. TITLE OF PROJECT (OR PROGRAM) (Limit to 56 spaces): A High Resolution
Physical Map of Human Chromosome 10 MGN

9. GRANTEE NAME AND ADDRESS:

Collaborative Research, Inc.
1365 Main Street
Waltham, MA 02154

10. DIRECTOR OF PROJECT (PROGRAM DIRECTOR/PRINCIPAL INVESTIGATOR) (LAST
NAME FIRST AND ADDRESS):

Mao, Jen-I PHD
Collaborative Research, Inc.
1365 Main Street
Waltham, MA 02154

-16-

11. APPROVED BUDGET (Excludes PHS Direct Assistance)

I PHS Grant Funds Only

/ I /

II Total project costs including grant funds and all
other financial participation

(SELECT ONE AND PLACE NUMERAL IN BOX.)

a. Salaries and Wages.................................$150,352
b. Fringe Benefits.....................................$51,118
c. Total Personnel Costs................................. $201,470
d. Consultant Costs........................................... 0
e. Equipment.................................................. 8,000
f. Supplies................................................... 105,000
g. Travel..................................................... 1,600
h. Patient Care--Inpatient.................................... 0
i. --Outpatient................................... 0
j. Alterations and Renovations................................ 0
k. Other...................................................... 7,150
l. Consortium/Contractual Costs............................... 0
m. Trainee Related Expenses...................................
n. Trainee Stipends........................................... 0
o. Trainee Tuition and Fees................................... 0
p. Trainee Travel............................................. 0
q. TOTAL DIRECT COSTS ->................................. $323,220
r. INDIRECT COSTS (Rate* % of S&W/TADC)................. $283,698
s. TOTAL APPROVED BUDGET...................................... $606,918
t. SBIR Fee................................................... $ 0
u. Federal Share.............................................. $606,918
v. Non-Federal Share.......................................... $

12. AWARD COMPUTATION FOR FINANCIAL ASSISTANCE

a. Amount of PHS Financial Assistance (from Item 11.u.)........... $606,918
b. Less Unobligated Balance From Prior Budge Periods.............. $ 0
c. Less Cumulative Prior Award(s) This Budget Period.............. $ 0
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION..................... $606,918

13. RECOMMENDED FUTURE SUPPORT (SUBJECT TO THE AVAILABILITY OF FUNDS AND
SATISFACTORY PROGRESS OF THE PROJECT):

a. 05 330,629 d.
- -------------------------------------------------------------------------------------------------------------------
b. 06 373,378 e.
- -------------------------------------------------------------------------------------------------------------------
c. f.
- -------------------------------------------------------------------------------------------------------------------

-17-

14. APPROVED DIRECT ASSISTANCE BUDGET (IN LIEU OF CASH):

15. PROGRAM INCOME SUBJECT TO 45 CFR PART 74, SUBPART F, OR 45 CFR 92.25,
SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:
(Select One and Place LETTER in box.)

/ B /
a. DEDUCTION
b. ADDITIONAL COSTS
c. MATCHING
d. OTHER RESEARCH (Add/Deduct Option)
e. OTHER (See REMARKS)

- --------------------------------------------------------------------------------
REMARKS: (Other Terms and Conditions Attached -- / X / Yes / / No)

Grant Specialist: Linda Hall (301) 402-0733
Program Official: Dr. Bettie J. Graham 301- 496-7531

* Base X Rate ($315,220 X 90.00)

This Grant is included under expanded authorities.
- --------------------------------------------------------------------------------

PHS GRANTS MANAGEMENT OFFICER: (Signature)
/s/ Jean M. Cahill
(Name-Typed/Print) (Title)
Jean M.Cahill Grants Management Officer

17. OBJ. CLASS: 41.4B

18. CRS - EIN: 1042297484A1

-18-

19. LIST NO.:

20.a. 94 8427201 b. R1HG00122B c. d. e.

21.a. b. c. d. e.

22.a. b. c. d. e.
- ---------------------------------------------------------------------------------------------------------------------------
PHS-5152-5 (Rev. 7/92): 940418 1149 (Note: See reverse for payment information) DC

-19-

NOTICE OF GRANT AWARD

Page 3
2 R01 HG00122-04
MAO, JEN-I, Ph.D.

Control of Government Property." The property administrator for the grant is:

Chief, Property Accountability Section
Personal Property Branch
National Institutes of Health
Building 13, Room 2E65
Bethesda, MD 20892
Phone: 301-496-6467

-20-

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE

National Institutes of Health
National Center for Human Genome Research

NOTICE OF GRANT AWARD
AUTHORIZATION (Legislation/Regulation)

42 USC 241 42 CFR 52
RESEARCH
REVISED
1. DATE ISSUED (Mo./Day/Yr.): 09/30/94

2. CFDA NO.: 93.172

3. SUPERSEDES AWARD NOTICE dated 04/22/94 except that any additions or
restrictions previously imposed remain in effect unless specifically
rescinded.

4. GRANT NO.: 2 R01 HG00122-04

Formerly:

5. ADMINISTRATIVE CODES: M2BG

6. PROJECT PERIOD Mo./Day/Yr.: From 05/01/91 Through 04/30/97

7. BUDGET PERIOD Mo./Day/Yr.: From 05/01/94 Through 04/30/95

8. TITLE OF PROJECT (OR PROGRAM) (Limit to 56 spaces): High resolution
physical MAP of chromosome 10 MGN

9. GRANTEE NAME AND ADDRESS:

Genome Therapeutics Corp.
100 Beaver Street
Waltham, MA 02154

10. DIRECTOR OF PROJECT (PROGRAM DIRECTOR/PRINCIPAL INVESTIGATOR) (LAST
NAME FIRST AND ADDRESS):

MAO, JEN-I PHD
Collaborative Research Inc.
1365 Main Street
Waltham, MA 02154

-21-

11. APPROVED BUDGET (Excludes PHS Direct Assistance)

I PHS Grant Funds Only

/ I /

II Total project costs including grant funds and all
other financial participation

(SELECT ONE AND PLACE NUMERAL IN BOX.)

a. Salaries and Wages......................................... $150,352
b. Fringe Benefits............................................ $ 51,118
c. Total Personnel Costs................................. $201,470
d. Consultant Costs........................................... 0
e. Equipment.................................................. 8,000
f. Supplies................................................... 105,000
g. Travel..................................................... 1,600
h. Patient Care--Inpatient.................................... 0
i. --Outpatient.............................. 0
j. Alterations and Renovations................................ 0
k. Other...................................................... 7,150
l. Consortium/Contractual Costs............................... 0
m. Trainee Related Expenses...................................
n. Trainee Stipends........................................... 0
o. Trainee Tuition and Fees................................... 0
p. Trainee Travel............................................. 0
q. TOTAL DIRECT COSTS ->................................. $323,220
r. INDIRECT COSTS (Rate* % of S&W/TADC).................... $283,698
s. TOTAL APPROVED BUDGET...................................... $606,918
t. SBIR Fee................................................... $ 0
u. Federal Share.............................................. $606,918
v. Non-Federal Share.......................................... $

12. AWARD COMPUTATION FOR FINANCIAL ASSISTANCE

a. Amount of PHS Financial Assistance (from Item 11.u.) $606,918
b. Less Unobligated Balance From Prior Budge Periods $ 0
c. Less Cumulative Prior Award(s) This Budget Period $606,918
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION $ 0

13. RECOMMENDED FUTURE SUPPORT (SUBJECT TO THE AVAILABILITY OF FUNDS AND
SATISFACTORY PROGRESS OF THE PROJECT):

- ---------------------------------------------------------------------------------------------------------------------------
YEAR TOTAL DIRECT COSTS/STIPENDS YEAR TOTAL DIRECT COSTS/STIPENDS
- ---------------------------------------------------------------------------------------------------------------------------

a. 05 330,629 d.
- ---------------------------------------------------------------------------------------------------------------------------
b. 06 373,378 e.
- ---------------------------------------------------------------------------------------------------------------------------
c. f.
- ---------------------------------------------------------------------------------------------------------------------------

-22-

14. APPROVED DIRECT ASSISTANCE BUDGET (IN LIEU OF CASH):

a. Amount of PHS Direct Assistance........................... $
b. Less Unobligated Balance From Prior Budget Periods........ $
c. Less Cumulative Prior Award(s) This Budget Period......... $
d. AMOUNT OF DIRECT ASSISTANCE THIS ACTION................... $

15. PROGRAM INCOME SUBJECT TO 45 CFR PART 74, SUBPART F, OR 45 CFR 92.25, SHALL
BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES: (Select One and
Place LETTER in box.)

a. DEDUCTION
b. ADDITIONAL COSTS
c. MATCHING
d. OTHER RESEARCH (Add/Deduct Option) / B /
e. OTHER (See REMARKS)

16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE
PHS ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS
INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:

- --------------------------------------------------------------------------------
REMARKS: (Other Terms and Conditions Attached -- / X / Yes / / No)

Grant Specialist: Linda Hall 301- 402-0733
Program Official: Dr. B. Graham 301- 496-7531

* Base X Rate ($315,220 x 90.00)

This Grant is included under expanded authorities.
- --------------------------------------------------------------------------------

PHS GRANTS MANAGEMENT OFFICER: (Signature)
/s/ Jean M. Cahill
(Name-Typed/Print) (Title)
Jean M. Cahill Grants Management Officer

17. OBJ. CLASS: 41.4B

18. CRS - EIN: 1042297484A1

-23-

19. LIST NO.:
- ---------------------------------------------------------------------------------------------------------------------------
FY-CAN DOCUMENT NO. ADMINISTRATIVE AMT. ACTION FIN. AMT. ACTION DIR.
CODE ASST. ASST.
- ---------------------------------------------------------------------------------------------------------------------------

20.a. 94 8427201 b. R1HG00122B c. d. e.

21.a. b. c. d. e.

22.a. b. c. d. e.
- ---------------------------------------------------------------------------------------------------------------------------
PHS-5152-5 (Rev. 7/92): 940928 0940 (Note: See reverse for payment information.) JP 01

-24-

NOTICE OF GRANT AWARD

Page 2
2 ROI HG00122-04
MAO, JEN-I, PH.D.

1. This award is revised to reflect the grantee's name change. The grantee's
name is changed from Collaborative Research, Inc. to Genome Therapeutics
Corporation as requested in letter dated September 12, 1994.

2. It is the current practice of the NCHGR to mail the original Notice of Grant
Award (NGA) and Terms and Conditions to the Business Official of the grantee
organization. Since this is the ONLY notification which will be provided to your
institution it is the responsibility of the grantee Business Office to make
distribution of the NGA and Terms and Conditions to the Principal Investigator
and other staff.

3. All previous terms and conditions remain in effect.

-25-

NOTICE OF GRANT AWARD
(ADDITIONAL REMARKS)

PAGE 3

If you need assistance form the National Center for Human Genome Research during
the course of this grant, please contact the grants management and program staff
whose telephone numbers are shown on the Notice of Grant Award. These
individuals work closely with one another through all phases and each project to
facilitate the award and the administration of the grant. Their functions are
defined as follows:

GRANTS MANAGEMENT CONTACT: The Grants Management Specialist, whose name and
telephone number are indicated in the "Remarks" section of the Notice of Grant
Award, is responsible for all business management matters associated with the
review, negotiation, award and administration of grants. The Grants Management
Specialist serves as the focal point for receiving and responding to all
questions and correspondence related to business management and policy matters,
such as correspondence giving or denying any prior approval required by Public
Health Service policy or special Terms of Award, transfer of the grant to
another institution, a change in the period of support, or any actions which
commit, or may result in committing the NCHGR to a change in the amount of
funding.

PROGRAM CONTACT: The Health Scientist Administrator, or program official, whose
name and telephone number also are indicated in the "Remarks" section of the
Notice of Grant Award, is responsible for all scientific and technical matters
dealing with the administration of the grant. The Health Scientist Administrator
reviews and monitors scientific progress of the project and provides advice and
assistance relative to all technical problems to ensure that the scientific
objectives of the research program can be pursued effectively and successfully.
All questions or correspondence dealing with research progress, changes in
research direction, unique scientific opportunities, or any other scientific
need should be addressed to the Health Scientist Administrator.

PRIOR APPROVAL: Requests which require the prior approval of the NCHGR must be
submitted in writing to the Grants Management Officer. All requests should
reference the complete grant number, e.g., 1 RO1 HG 12345-01, and must be signed
by the authorized official of the business office of the grantee institution and
by the principal investigator.

-26-

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
National Institutes of Health
National Center for Human Genome Research

NOTICE OF GRANT AWARD
AUTHORIZATION (Legislation/Regulation)

42 USC 241 42 CFR 52
RESEARCH

1. DATE ISSUED (Mo./Day/Yr.): April 13, 1995

2. CFDA NO.: 93-172

3. SUPERSEDES AWARD NOTICE dated __________________ except that any
additions or restrictions previously imposed remain in effect unless
specifically rescinded.

4. GRANT NO.: 5 R01 HG00122-05

Formerly:

5. ADMINISTRATIVE CODES: M2BG

6. PROJECT PERIOD Mo./Day/Yr.: From 05/01/91 Through 04/30/97

7. BUDGET PERIOD Mo./Day/Yr.: From 05/01/95 Through 04/30/96

8. TITLE OF PROJECT (OR PROGRAM) (Limit to 56 spaces): High Resolution
Physical Map of Chromosome 10 MGN

9. GRANTEE NAME AND ADDRESS:

Genome Therapeutics Corporation
100 Beaver Street
Waltham, MA 02154

10. DIRECTOR OF PROJECT (PROGRAM DIRECTOR/PRINCIPAL INVESTIGATOR)
(LAST NAME FIRST AND ADDRESS):

MAO, JEN-I PHD
Collaborative Research Division
Genome Therapeutics Corporation
100 Beaver Street
Waltham, MA 02154

11. APPROVED BUDGET (Excludes PHS Direct Assistance)

I PHS Grant Funds Only

/ I /
II Total project costs including grant funds and all
other financial participation

(SELECT ONE AND PLACE NUMERAL IN BOX.)

a. Salaries and Wages.............................$156,366
b. Fringe Benefits.................................$53,163
c. Total Personnel Costs............................ $209,529
d. Consultant Costs...................................... 0
e. Equipment............................................. 5,000
f. Supplies.............................................. 109,200
g. Travel................................................ 1,600
h. Patient Care--Inpatient............................... 0
i. --Outpatient.............................. 0
j. Alterations and Renovations........................... 0
k. Other................................................. 5,300
l. Consortium/Contractual Costs.......................... 0
m. Trainee Related Expenses..............................
n. Trainee Stipends...................................... 0
o. Trainee Tuition and Fees.............................. 0
p. Trainee Travel........................................ 0
q. TOTAL DIRECT COSTS ->............................ $330,629
r. INDIRECT COSTS (Rate* % of S&W/TADC)............ $293,066
s. TOTAL APPROVED BUDGET................................. $623,695
t. SBIR Fee.............................................. $ 0
u. Federal Share......................................... $623,695
v. Non-Federal Share..................................... $

12. AWARD COMPUTATION FOR FINANCIAL ASSISTANCE

a. Amount of PHS Financial Assistance (from Item 11.u.).... $623,695
b. Less Unobligated Balance From Prior Budge Periods....... $ 0
c. Less Cumulative Prior Award(s) This Budget Period....... $ 0
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION.............. $623,695

13. RECOMMENDED FUTURE SUPPORT (SUBJECT TO THE AVAILABILITY OF FUNDS AND
SATISFACTORY PROGRESS OF THE PROJECT):

a. 06 373,378 d.
- ---------------------------------------------------------------------------------------------------------------------------
b. e.
- ---------------------------------------------------------------------------------------------------------------------------
c. f.
- ---------------------------------------------------------------------------------------------------------------------------

-2-

14. APPROVED DIRECT ASSISTANCE BUDGET (IN LIEU OF CASH):

a. Amount of PHS Direct Assistance....................... $
b. Less Unobligated Balance From Prior Budget Periods.... $
c. Less Cumulative Prior Award(s) This Budget Period..... $
d. AMOUNT OF DIRECT ASSISTANCE THIS ACTION............... $

15. PROGRAM INCOME SUBJECT TO 45 CFR PART 74, SUBPART F, OR 45 CFR 92.25,
SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES: (Select
One and Place LETTER in box.)

/ B /
a. DEDUCTION
b. ADDITIONAL COSTS
c. MATCHING
d. OTHER RESEARCH (Add/Deduct Option)
e. OTHER (See REMARKS)

- --------------------------------------------------------------------------------
REMARKS: (Other Terms and Conditions Attached -- / X / Yes / / No)

Grant Specialist: Linda Hall (301) 402-0733
Program Official: Dr. B. Graham 301- 496-7531

* Base X Rate ($325,629 X 90.00)

This Grant is included under expanded authorities.
- --------------------------------------------------------------------------------

PHS GRANTS MANAGEMENT OFFICER: (Signature)
/s/ Jean M. Cahill
(Name-Typed/Print) (Title)
Jean M. Cahill Grants Management Officer

17. OBJ. CLASS: 41.4E

18. CRS - EIN: 1042297484A1

-3-

20.a. 95 8427201 b. R1HG00122B c. d. e.

21.a. b. c. d. e.

22.a. b. c. d. e.
- ---------------------------------------------------------------------------------------------------------------------------
PHS-5152-5 (Rev. 7/92): 950406 1705 (Note: See reverse for payment information) LHJ HG/PC

-4-

NOTICE OF GRANT AWARD

Page 2
5 R01 HG00122-05
MAO, JEN-I, PH.D.

1. The Fiscal 1995 Appropriations Act prohibits reimbursement of direct salary
for individuals at a rate greater than $125,000 per year as determined in the
original award. The language contained in the Appropriations Act follows:

"None of the funds appropriated in this title for the National Institutes
of Health and the Substance Abuse and Mental Health Services Administration
shall be used to pay the salary of an individual through a grant or other
extramural mechanism at a rate in excess of $125,000 per year."

3. Pursuant to the NIH Revitalization Act (P.L. 103-43, June 10, 1993), Section
2004, when purchasing equipment or products under this assistance award, the
recipient should whenever possible, purchase only American-made items.

4. Allowable costs of activities conducted by for-profit organizations will be
determined by applying the costs principles of Contracts with Commercial
Organizations set forth in 48 CFR 31.2. However, independent research and
development costs (including the indirect costs allocable to them) are
unallowable.

5. Normally, the awardee organization retains the principal worldwide patent
rights to any invention developed with United States government support. Under
Title 37 Code of Federal Regulations Part 401, the Government receives a
royalty-free license for its use, reserves the right to require the patent
holder to license others in certain circumstances, and requires that anyone
exclusively licensed to sell the invention in the United States must normally
manufacture it substantially in the United States. To the extent authorized by
Title 35 United States Code Section 205, the Government will not make public any
information disclosing a Government-supported invention for a 4-year period to
allow the awardee organization a reasonable time to file a patent application,
nor will the Government release any information that is part of that
application.

-5-

NOTICE OF GRANT AWARD

Page 3
5 R01 HG00122-05
MAO, JEN-I, PH.D.

6. Any invention, developed under this award should be reported to the Patent
Branch, DHHS, NIH, Office of Technology Transfer, 6011 Executive Blvd., Room
325, Rockville, Maryland 20892- 3804. Phone (301) 496-7056, for disposition of
patent rights in accordance with 45 CFR, Parts 6 and 8. Disposition rights on
inventions made by small businesses are subject to Chapter 18 of Title 35 U.S.
Code.

7. Prior approval to implement budgetary and programmatic changes, where
required by PHS Policy, must be obtained in writing from the Grants Management
contact shown on this Notice of Grant Award.

8. Applicant organization must comply with the Public Health Service (PHS)
policy relating to distribution of unique research resources produced with PHS
funding (NIH Guide for Grants and Contracts, Vol 20, No. 5, February, 1991).
Grantee should also comply with the NIH-DOE guidelines for access to mapping and
sequencing data and materials resources, adopted by the NIH- DOE joint
subcommittee on December 7, 1992 (see attached).

-6-

34
NOTICE OF GRANT AWARD
(ADDITIONAL REMARKS)

Page 4

If you need assistance from the National Center for Human Genome Research during
the course of this grant, please contact the grants managementr and program
staff whose telephone numbers are shown on the Notice of Grant Award. These
individuals work closely with one another through all phases of each project to
facilitate the award and the administration of the grant. Their functions are
defined as follows:

GRANT MANAGEMENT CONTACT: The Grants Management Specialist, whose name and
telephone numnber are indicated in the "Remarks" sectionof the Notice of Grant
Award, is responsible for all business management matters associated with the
review, negotiation, award, and administration of grants. The Grants Management
Specialist serves as the focal point for receiving and responding to all
questions and correspondence related to business management and policy matters,
such as correspondence giving or denying any prior approval required by Public
Health Service policy or special Terms of Award, transfer of the grant to
another institution, a change in the period of support, or any actions which
commit, or may result in committing the NCHGR to a change in the amount of
funding.

PRIOR APPROVAL: Requests which require the prior approval of the NCHGR must be
submitted in writing to the Grants Management Officer. All requests should
reference the complete grant number, e.g., 1 R01 HG12345-01, and must be signed
by the authorized official of the business office of the grantee institution and
by the principal investigator.

-7-

NIH-DOE GUIDELINES FOR ACCESS TO MAPPING AND
SEQUENCING DATA AND MATERIAL RESOURCES(1)

The information and resources generated by the Human Gemone Project have become
substantial, and the interest in having access to them is widespread. It is
therefore desirable to have a statement of philosophy concerning the sharing of
these resources that can guide investigators who generate the resources as well
as those who wish to use them.

A key issue for the Human Genome Project is how to promote and encourage the
rapid sharing of material and data that are produced, especially information
that has not yet been published or may never be published or may never be
published in its entirety. Such sharing is essential for progress toward the
goals of the program and to avoid unnecessary duplication. It is also desirable
to make the fruits of genome research available to the scientific community as a
whole as soon as possible to expedite research in other areas.

Although it is the policy of the Human Genome Project to maximize outreach to
the scientific community, it is also necessary to give investigators time to
verify the accuracy of their data and to gain some scientific advantage from the
effort they have invested. Furthermore, in orderto assure that novel ideas and
inventions are rapidly developed to the benefit of the public, intellectual
property protection may be needed for some of the data and materials.

After extensive discussion with the community of genome researchers, the
advisors of the NIH and DOE genome programs have determined that consensus is
developing around the concept that a 6 month period from the time the data or
materials are generated to the time they are made available publicly is a
reasonable maximum in almost all cases. More rapid sharing is encouraged.

Whenever possible, data should be deposited in public databases and materials in
public repositories. Where appropriate repositories do not exist or are unable
to accept the data or materials, investigators should accomodate requests to the
extent possible.

The NIH and DOE genome programs have decided to require all applicants expecting
to generate significant amounts of genome data or materials to describe in their
application how and when they plan to make such data and materials available to
the community. Grant solicitations will specify this requirement. These plans in
each application will be reviewed in the course of peer review and by staff to
assure they are reasonable and in conformity with program philosophy. If a grant
is made, the applicant's sharing plans will become a condition of the award and
compliance will be reviewed before continuation is provided. Progress reports
will be asked to address the issue.

- -------------------------
(1) Adopted by the NIH-DOE Joint Subcommittee, December 7, 1992.

-8-